肠道类器官模拟炎症性肠病

IF 1.2 Q4 PHARMACOLOGY & PHARMACY
Cristina Di Giorgio, Rosalinda Roselli, Michele Biagioli, Martina Bordoni, Patrizia Ricci, Angela Zampella, Eleonora Distrutti, Annibale Donini, Stefano Fiorucci
{"title":"肠道类器官模拟炎症性肠病","authors":"Cristina Di Giorgio,&nbsp;Rosalinda Roselli,&nbsp;Michele Biagioli,&nbsp;Martina Bordoni,&nbsp;Patrizia Ricci,&nbsp;Angela Zampella,&nbsp;Eleonora Distrutti,&nbsp;Annibale Donini,&nbsp;Stefano Fiorucci","doi":"10.2174/2772270817666221121143853","DOIUrl":null,"url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD) is a chronic and relapsing disease caused by a dysregulated immune response to host intestinal microbiota that occurs in genetically predisposed individuals. IBD encompasses two major clinical entities: ulcerative colitis (UC), limited to the colonic mucosa, and Crohn's disease (CD), which might affect any segment of the gastrointestinal tract. Despite the prevalence of IBD increasing worldwide, therapy remains suboptimal, largely because of the variability of causative mechanisms, raising the need to develop individualized therapeutic approaches targeted to each individual patient. In this context, patients-derived intestinal organoids represent an effective tool for advancing our understanding of IBD's pathogenesis. Organoid 3D culture systems offer a unique model for dissecting epithelial mechanisms involved IBDs and testing individualized therapy, although the lack of a functional immune system and a microbiota, two driving components of the IBD pathogenesis, represent a major barrier to their exploitation in clinical medicine. In this review, we have examined how to improve the translational utility of intestinal organoids in IBD and how co-cultures of 3D or 2D organoids and immune cells and/or intestinal microbiota might help to overcome these limitations.</p>","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Modeling Inflammatory Bowel Disease by Intestinal Organoids.\",\"authors\":\"Cristina Di Giorgio,&nbsp;Rosalinda Roselli,&nbsp;Michele Biagioli,&nbsp;Martina Bordoni,&nbsp;Patrizia Ricci,&nbsp;Angela Zampella,&nbsp;Eleonora Distrutti,&nbsp;Annibale Donini,&nbsp;Stefano Fiorucci\",\"doi\":\"10.2174/2772270817666221121143853\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Inflammatory bowel disease (IBD) is a chronic and relapsing disease caused by a dysregulated immune response to host intestinal microbiota that occurs in genetically predisposed individuals. IBD encompasses two major clinical entities: ulcerative colitis (UC), limited to the colonic mucosa, and Crohn's disease (CD), which might affect any segment of the gastrointestinal tract. Despite the prevalence of IBD increasing worldwide, therapy remains suboptimal, largely because of the variability of causative mechanisms, raising the need to develop individualized therapeutic approaches targeted to each individual patient. In this context, patients-derived intestinal organoids represent an effective tool for advancing our understanding of IBD's pathogenesis. Organoid 3D culture systems offer a unique model for dissecting epithelial mechanisms involved IBDs and testing individualized therapy, although the lack of a functional immune system and a microbiota, two driving components of the IBD pathogenesis, represent a major barrier to their exploitation in clinical medicine. In this review, we have examined how to improve the translational utility of intestinal organoids in IBD and how co-cultures of 3D or 2D organoids and immune cells and/or intestinal microbiota might help to overcome these limitations.</p>\",\"PeriodicalId\":29815,\"journal\":{\"name\":\"Recent Advances in Inflammation & Allergy Drug Discovery\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recent Advances in Inflammation & Allergy Drug Discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/2772270817666221121143853\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent Advances in Inflammation & Allergy Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2772270817666221121143853","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

炎症性肠病(IBD)是一种慢性和复发性疾病,由对宿主肠道微生物群的免疫反应失调引起,发生在遗传易感个体中。IBD包括两个主要的临床实体:溃疡性结肠炎(UC),局限于结肠粘膜,克罗恩病(CD),可能影响胃肠道的任何部分。尽管IBD的患病率在全球范围内不断增加,但治疗方法仍然不是最佳的,这主要是因为致病机制的可变性,因此需要针对每个患者开发个性化的治疗方法。在这种情况下,患者来源的肠道类器官是促进我们对IBD发病机制理解的有效工具。类器官3D培养系统提供了一种独特的模型,用于解剖涉及IBD的上皮机制和测试个体化治疗,尽管缺乏功能性免疫系统和微生物群,这是IBD发病机制的两个驱动因素,是临床医学开发的主要障碍。在这篇综述中,我们研究了如何提高肠道类器官在IBD中的转化效用,以及如何将3D或2D类器官与免疫细胞和/或肠道微生物群共同培养有助于克服这些局限性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Modeling Inflammatory Bowel Disease by Intestinal Organoids.

Inflammatory bowel disease (IBD) is a chronic and relapsing disease caused by a dysregulated immune response to host intestinal microbiota that occurs in genetically predisposed individuals. IBD encompasses two major clinical entities: ulcerative colitis (UC), limited to the colonic mucosa, and Crohn's disease (CD), which might affect any segment of the gastrointestinal tract. Despite the prevalence of IBD increasing worldwide, therapy remains suboptimal, largely because of the variability of causative mechanisms, raising the need to develop individualized therapeutic approaches targeted to each individual patient. In this context, patients-derived intestinal organoids represent an effective tool for advancing our understanding of IBD's pathogenesis. Organoid 3D culture systems offer a unique model for dissecting epithelial mechanisms involved IBDs and testing individualized therapy, although the lack of a functional immune system and a microbiota, two driving components of the IBD pathogenesis, represent a major barrier to their exploitation in clinical medicine. In this review, we have examined how to improve the translational utility of intestinal organoids in IBD and how co-cultures of 3D or 2D organoids and immune cells and/or intestinal microbiota might help to overcome these limitations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
33
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信